Report Highlights Vaccine Portfolio and Innovation
On April 30, 2026, Sinovac Biotech Ltd., a renowned biopharmaceutical company based in China, submitted its 2024 annual report on Form 20-F to the U.S. Securities and Exchange Commission. This report is now accessible on both the company's investor relations website and the SECs official website.
The annual report by Sinovac outlines a diverse vaccine portfolio, including vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease, poliomyelitis, and pneumococcal disease. Three of these vaccines have received prequalification from the World Health Organisation: the inactivated hepatitis A vaccine Healive4ae, the Sabin-strain inactivated polio vaccine (sIPV), and the varicella vaccine.
During past public health crises, such as the outbreaks of SARS, H5N1, H1N1, and COVID-19, SINOVAC demonstrated its leadership in vaccine development. The company was among the first to engage in research and development during these emergencies and successfully developed CoronaVac4ae, which has become the most widely used inactivated COVID-19 vaccine globally.
SINOVAC developed the world9s first inactivated SARS vaccine, China9s first H5N1 influenza vaccine (Panflu4ae), and the first H1N1 influenza vaccine (Panflu.14ae). These milestones highlight the company's pioneering role in addressing infectious disease outbreaks.
Advancements in Vaccine Technology
The company is advancing a robust pipeline that includes combination vaccines and recombinant protein vaccines. SINOVAC is exploring next-generation platforms such as mRNA technologies and antibodies. These innovations are designed to meet unmet medical needs and enhance global pandemic preparedness.
Actively expanding its global presence, SINOVAC is forging partnerships with research institutions, international organisations, and local partners. By increasing its market presence and engaging in technological cooperation, the company aims to accelerate vaccine development and supply, thereby improving regional access to high-quality products.
Localized production enhances regional access to vaccines and addresses global health challenges effectively. This approach aligns with SINOVAC9s mission to eliminate human diseases through vaccination.
For comprehensive information regarding SINOVAC9s initiatives and vaccine portfolio, interested parties can view the full annual report on SINOVAC9s website and the SEC9s official portal.
